MedPath

Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers

Not Applicable
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Other: Native palm olein (IV56)
Other: High oleic sunflower oil
Other: Chemically interesterified palm olein (IV56)
Registration Number
NCT01906359
Lead Sponsor
Malaysia Palm Oil Board
Brief Summary

Type 2 diabetes mellitus (T2DM) is a chronic disorder determined by lifestyle and genes. It is associated with chronic hyperglycaemia along with other metabolic abnormalities. It is also one of the risk factors for cardiovascular disease (CVD). This disease is due to insulin resistance and/or deficiency as well as increased hepatic glucose output. According to the Third National Health and Morbidity Survey (3rd NHMS), the prevalence of T2DM for adults aged 30 years and above is 14.9%, increased by almost 80% from 1996 to 2006. Dietary composition may affect insulin sensitivity, postprandial triacylglycerol concentration and the risk of T2DM. The role of dietary fats in T2DM is of particular interest and has been clinically studied for many decades. The type of fat we ingest every day consists of different types of fatty acids and different degree of saturation, which in turn influence glucose metabolism by altering cell membrane function, enzyme activity, insulin signalling and gene expression. Previous studies demonstrated that interesterification of dietary fat alter postprandial lipaemia. Saturated fat such as palm olein has been reported to display lower postprandial lipaemia after interesterification. Changing the structure of triacylglycerol (TAG) alters the physical properties of dietary fat which affects digestibility, metabolism and atherogenicity. A recent study conducted by Sanders and co-workers demonstrated reduced levels of plasma glucose-dependent insulinotropic polypeptide (GIP) following both the lard and interesterified palm olein (IPO) compared with the palm olein (PO) and high oleic sunflower oil (HOS) diets in healthy subjects. The GIP and glucagon-like peptide-1 (GLP-1) are major players in the modulation of postprandial insulin secretion by the pancreas. Although GIP secretion in response to meals is normal in patients with Type 2 diabetes mellitus (T2DM), GIP induced secretion of insulin is defective in diabetes. This is observed to be predominantly a defective stimulation of the late phase of insulin response (20-120 minutes). The effect of IPO on GIP may be exaggerated in T2DM patients with impaired insulin sensitivity. Hence, IPO may change the concentrations of gut hormones, postprandial lipaemia, insulinaemic response and CVD related haemostatic markers.

Detailed Description

Subjects aged between 30 and 60 years old (male and female) with Type 2 diabetes mellitus (T2DM) will be recruited for this study. A randomized, crossover, double-blind study design will be carried out to investigate the acute effects of high fat meals prepared using palm olein (PO), chemically interesterified palm olein (IPO) and high oleic sunflower oil (HOS) (control) on study subjects with T2DM. Study subjects will have to undergo three postprandial challenges, separated by at least one week interval. Fasting blood sample and duplicate baseline blood samples will be taken in the morning of postprandial day. After that, subjects will be asked to consume a test meal consisting a high fat muffin baked using the aforementioned oils and a milkshake within 10 minutes. After meal, venous blood samples will be taken at time-points 15, 30, 60, 90, 120 min, 3 h, 4 h, 5 h, 6 h and post-heparin plasma 5 min and 15 min for analysis. Pulse wave analysis will be conducted to evaluate central blood pressure and arterial stiffness. Meal appreciation will be assessed by utilising visual analogue scale (VAS) before eating, after eating and at each time-point.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
23
Inclusion Criteria
  1. Mild T2DM individuals not planned for medical intervention

    • 7.0 mmol/L ≤ fasting glucose ≤ 11.1 mmol/L
    • 6.5% ≤ HbA1c ≤ 9.0%
    • Not using antihypertensive, lipid lowering, insulin/glucose modulating medication
  2. Mild T2DM individuals currently on medical intervention

    • Fasting glucose ≤ 11.1 mmol/L
    • HbA1c ≤ 9.0%
    • Using antihypertensive, lipid lowering or glucose modulating medication
  3. Malaysian male or female with T2DM aged between 30 to 60 years old

  4. Not using insulin

  5. Not having any complications of diabetes

  6. No medical history of myocardial infarction, angina, thrombosis, stroke or cancer

  7. Haemoglobin levels for females ≥ 11.5 gm/dl and males ≥ 12.5 gm/dl

  8. Serum ferritin > 15 µg/l at commencement of study

Exclusion Criteria
  1. Medical history of myocardial infarction, angina, thrombosis, stroke or cancer
  2. Underweight (BMI < 18.5 kg/m²)
  3. Using insulin
  4. Total cholesterol > 7.0 mmol/L
  5. Abnormal liver function, renal function and haematology
  6. Hypersensitive towards heparin
  7. Gastric or lactose intolerance
  8. Smoker
  9. Pregnancy and lactating
  10. Taking alcohol
  11. Taking alcohol
  12. Haemoglobin levels for females ≤ 11.5 gm/dl and males ≤ 12.5 gm/dl
  13. Serum ferritin < 15 µg/l at commencement of study

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Dietary fat - PONative palm olein (IV56)Native palm olein (IV56)
Dietary fat - HOSHigh oleic sunflower oilHigh oleic sunflower oil
Dietary fat - IPOChemically interesterified palm olein (IV56)Chemically interesterified palm olein (IV56)
Primary Outcome Measures
NameTimeMethod
6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP)0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour

To determine the postprandial changes of GIP.

Secondary Outcome Measures
NameTimeMethod
6-hour postprandial changes from fasting in gut hormones0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 h

To determine the postprandial changes of ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and cholecystokinin (CCK).

6-hour postprandial changes from fasting in insulinaemic response0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour

To determine the postprandial changes of glucose, insulin, C-peptide and non-esterified fatty acid (NEFA)

6-hour postprandial changes from fasting in lipaemia0, 1, 2, 3, 4, 5, 6 hour for TAG and apoB48; 6 hour postheparin for LPL; pooled 3, 4, 5 hour for chylomicron and PFA

To determine the postprandial changes of triacylglycerol (TAG) and apolipoprotein B48 (apoB48).

To compare lipoprotein lipase (LPL) activity, chylomicron fatty acid composition and plasma fatty acid (PFA) composition across meals.

6-hour postprandial changes from fasting in haemostatic response0, 2, 4, 6 hour for FVIIa, PAI-1 and D-dimer; 0, 4 hour for PWA

To determine the postprandial changes of factor FVII activation (FVIIa), plasminogen activator inhibitor-1 (PAI-1)and D-dimer.

To compare pulse wave analysis (PWA) across meals.

6-hour changes from fasting hunger rating using visual analogue scale (VAS)0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour

To determine the changes in hunger rating and food satiety

Trial Locations

Locations (5)

Hulu Langat District Health Office

🇲🇾

Kajang, Selangor, Malaysia

Malaysian Palm Oil Board (MPOB)

🇲🇾

Kajang, Selangor, Malaysia

Universiti Putra Malaysia

🇲🇾

Serdang, Selangor, Malaysia

Selangor State Health Office

🇲🇾

Shah Alam, Selangor, Malaysia

Sepang District Health Office

🇲🇾

Sepang, Selangor, Malaysia

© Copyright 2025. All Rights Reserved by MedPath